Search

Displaying results 2791 - 2800 of 10000 in total
  1. Drug

    EDIT-101

    go.drugbank.com/drugs/DB18687
    Investigational

    EDIT-101 is a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing

    Synonyms: a recombinant adeno-associated virus pseudotyped with serotype 5 viral capsid encoding CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats associated protein 9) gene editing constructs
  2. Drug

    Digoxin

    go.drugbank.com/drugs/DB00390
    ApprovedInvestigational

    [A178225] It is a common agent used to manage atrial fibrillation and the symptoms of heart failure. … [A178234] Digoxin is classified as a cardiac glycoside and was initially approved by the FDA in 1954.

    International brands: Digocard-GCategories: P-glycoprotein substrates with a Narrow Therapeutic Index, P-glycoprotein inducers
  3. Drug

    Pindolol

    go.drugbank.com/drugs/DB00960
    ApprovedInvestigational

    [A231064] Pindolol was granted FDA approval on 3 September 1982.[L32348] … [L32353] Early research into the use of pindolol found it had chronotropic effects, and so further investigation focused on the treatment of arrhythmia.

    Categories: Serotonin 5-HT1 Receptor Antagonists, Serotonin 5-HT1A Receptor AntagonistsSynonyms: 1-(1H-indol-4-yloxy)-3-(propan-2-ylamino)-propan-2-ol, 1-(1H-indol-4-yloxy)-3-(isopropylamino)propan-2-ol
  4. Drug

    Repaglinide

    go.drugbank.com/drugs/DB00912
    ApprovedInvestigational

    Approximately 90% of a single orally administered dose is eliminated in feces and 8% in urine. … In addition to reducing postprandial and fasting blood glucose, meglitnides have been shown to decrease glycosylated hemoglobin (HbA1c) levels, which are reflective of the last 8-10 weeks of glucose control

    Mixtures: PAREGLIN 1 MG/500 MG FILM KAPLI TABLET, 90 ADET, PAREGLIN 2 MG/500 MG FILM KAPLI TABLET, 90 ADETCategories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 Substrates
  5. Drug

    TAK-071

    go.drugbank.com/drugs/DB18954
    Investigational

    TAK-071 is under investigation in clinical trial NCT04334317 (A Study of TAK-071 in People With Parkinson Disease).

    Categories: Heterocyclic Compounds, 1-Ring, Heterocyclic Compounds, 2-RingSynonyms: 4-fluoro-2-((3s, 4s)-4-hydroxytetrahydro-2h-pyran-3-yl)-5-methyl-6-(4(1h-pyrazol-1-yl)benzyl)-2, 3-dihydro-1h-isoindol-1-one
  6. Drug

    Padnarsertib

    go.drugbank.com/drugs/DB19243
    Investigational

    Synonyms: 2-propenamide, 3-(6-amino-3-pyridinyl)-n-((5-(4-((4,4-difluoro-1-piperidinyl)carbonyl)phenyl)-7-(4-fluorophenyl)-2-benzofuranyl)methyl)-, (2e)-, Pak4-in-1Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    BMX-001 free base

    go.drugbank.com/drugs/DB17516
    Investigational

    Synonyms: Manganese(5+), ((2,2',2'',2'''-(21h,23h-porphine-5,10,15,20-tetrayl-.kappa.n21,.kappa.n22,.kappa.n23,.kappa.n24)tetrakis(1-(2-butoxyethyl)pyridiniumato))(2-))-, (sp-4-1)-
  8. Drug

    Busulfan

    go.drugbank.com/drugs/DB01008
    ApprovedInvestigational

    Busulfan is a bifunctional alkylating agent, having a selective immunosuppressive effect on bone marrow. It is not a structural analog of the nitrogen mustards. … According to the Fourth Annual Report on Carcinogens (NTP 85-002, 1985), busulfan is listed as a known carcinogen.

    Synonyms: 1, 4-Bis[methanesulfonoxy]butaneCategories: Cytochrome P-450 CYP3A4 Substrates with a Narrow Therapeutic Index, Cytochrome P-450 Substrates
  9. Drug

    Erlotinib

    go.drugbank.com/drugs/DB00530
    ApprovedInvestigational

    Erlotinib binds to the epidermal growth factor receptor (EGFR) tyrosine kinase in a reversible fashion at the adenosine triphosphate (ATP) binding site of the receptor. … It is typically marketed under the trade name Tarceva.

    Synonyms: [6,7-Bis-(2-methoxy-ethoxy)-quinazolin-4-yl]-(3-ethynyl-phenyl)-amineCategories: Heterocyclic Compounds, 2-Ring, Cytochrome P-450 CYP1A2 Substrates with a Narrow Therapeutic Index
  10. Drug

    Eltrombopag

    go.drugbank.com/drugs/DB06210
    ApprovedInvestigational

    ITP is a condition that may cause unusual bruising or bleeding due to an abnormally low number of platelets in the blood. … Eltrombopag has also been recently approved (late 2012) for the treatment of thrombocytopenia (low blood platelet counts) in patients with chronic hepatitis C to allow them to initiate and maintain interferon-based

    Categories: Heterocyclic Compounds, 1-Ring, Cytochrome P-450 SubstratesProducts: REVOLADE ® TABLETAS 50 MG, ROMPAG 50 MG FİLM KAPLI TABLET, 14 ADET